Apollo Hospitals Enterprise Management Guidance Tracker

Management reiterated that Apollo 24|7 is on track to achieve operational breakeven in Q4 FY24, with EBITDA loss narrowing to INR 57 crore in Q1.

Management expects to reach 70% occupancy over time without requiring significant capital expenditure, leveraging existing capacity.

The digital health platform is expected to achieve operational breakeven by the fourth quarter of FY24.

Digital platform expected to achieve profitability within six to eight quarters, driven by new verticals like insurance distribution and digital therapeutics.

Targeting GMV of INR 1,700 crore per quarter and take rate improvement from 4% to 8%.

The digital segment is on track to achieve breakeven within the next six to seven quarters, supported by GMV growth and cost control.

The online 24/7 platform is expected to achieve breakeven by Q2 FY26, with sustainable GMV growth and reduced marketing spend.

Digital platform expected to achieve EBITDA break-even by end of Q2 or Q3 of next fiscal year, with GMV target of INR 900-1,000 crore.

Apollo 24/7 is on track to achieve cash break-even between Q3 and Q4 of FY26, driven by cost reduction and revenue growth.

Digital business expected to achieve EBITDA breakeven by end of fiscal year, with GMV run-rate of INR 800-900 crore.

Management expects healthcare services organic growth to revert to 13% as Bangladesh patients return (60% already back in October) and new markets are explored.

Cash EBITDA breakeven for Apollo 24/7 pushed out by one quarter to Q1 FY27 due to insurance revenue recognition changes.

Management guided for combined pharmacy (offline + online) to reach INR 10,000 crore revenue and 6% EBITDA margins, with 500-600 new store additions planned for FY24.

Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.

Management expects 15% revenue growth for the full year, with Q3 impacted by seasonality but confident of achieving at least 14%.

Driven by volume growth, network expansion, and better asset utilization.

Management guided for ARPOB increase of 7% for the full year, supported by tariff revision of 4%, better case mix, and international patient recovery.

Including Keimed, the pharmacy platform targets INR 25,000 crore revenue with 7-8% EBITDA margin.

Apollo HealthCo (including Keimed) targets INR 25,000 crore revenue and 7-8% EBITDA margin by FY27.

Management expects organic revenue growth of low-to-mid teens for healthcare services in FY26, with new hospitals contributing from FY27.

Apollo HealthCo (including Keimed) targets revenue of INR 24,000 crore in FY27, with exit run rate crossing INR 25,000 crore.

Combined entity targeting INR 25,000 crore revenue with 7% EBITDA margin by end of FY27.

Management guided that online pharmacy discounts will remain in the 13-14% range for the rest of FY24, with offline discounts at 12-12.5%.

Management expects hospital EBITDA margins to improve by 200 basis points over the next two years, driven by operating leverage and occupancy improvement.

Internal target to increase EBITDA margins by 200 basis points through volume growth, clinical program expansion, and cost rationalization.

Targeting 25% margin by end of FY25 through cost optimization and surgical volume growth.

Management expects healthcare services EBITDA margin to expand by 100 basis points over the next 3-4 quarters, driven by volume growth, case mix improvement, and cost optimization.

Management expects 50-60 bps margin expansion for the full year, lower than initial 100-150 bps due to Bangladesh headwinds.

Healthcare services EBITDA margin expected to remain around 24% next year, with new bed openings impacting margins by no more than 100 bps.

Blended EBITDA margin for HealthCo (including Keimed) is expected to exceed 7% by FY27, driven by digital break-even and margin expansion.

Existing hospital margins expected to expand to 25%+ before new bed dilution of ~100bps.

Digital platform on course to break even by end of fiscal year, with all three lines (pharmacy, diagnostics, consults) already CM1 positive.

Apollo HealthCo targeting INR 25,000 crore revenue run rate with 7% EBITDA margin by Q4 FY27, supported by KEIMED integration and digital break-even.

Management expects total startup losses of INR 150 crore from new hospitals in FY27, with potential quarterly peaks of INR 50 crore.

Management expects 100 bps margin improvement in existing hospitals next year through asset utilization and cost optimization.

Apollo plans to add 2,300 beds across eight locations over the next three financial years, with a capital outlay of INR 3,400 crore.

Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.

Offline pharmacy network expansion to continue at similar pace as FY24.

Apollo HealthCo plans to add 500-550 new offline pharmacy stores in FY25, with Q1 impacted by election delays but pace expected to pick up.

Six facilities in key metros will be commissioned in FY26; half of the beds operationalized in FY26, rest in FY27 to protect margins.

Pune and Kolkata hospitals to open in H1 FY26; Hyderabad and Gurugram by end of FY26; 50% of 1,737 beds operational in FY26, rest in FY27.

New hospitals in Delhi, Pune, Bangalore, and Kolkata to add 700 beds during FY26.

Pune and Defence Colony in Q3, Sarjapur and Kolkata in Q4, Hyderabad and Gurugram in Q1 FY27. Aggregate EBITDA losses from these hospitals expected at ~INR 150 crore in FY27.

Approximately 1,500 new beds will be added across four new hospitals, with ~50% operationalized in FY27 and balance in early FY28.